Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Landay

Showing results (31-40 of 222) with videos related to

Pageof 23
Sort By:
Immunology|January 10, 2003
CD1d-restricted natural killer T cells are potent targets for human immunodeficiency virus infectionRichardson Fleuridor, Brian Wilson, Runhua Hou, et al.
The Journal of Infectious Diseases|July 11, 2003
Correlates of immune activation marker changes in human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women who use illicit drugsAlan Landay, Lorie Benning, James Bremer, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|February 5, 2011
A randomized trial of interleukin-2 during withdrawal of antiretroviral treatmentRonald J Bosch, Richard B Pollard, Alan Landay, et al.
AIDS Research and Therapy|August 7, 2010
Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328)Ronald J Bosch, Richard B Pollard, Alan Landay, et al.
Clinical and Vaccine Immunology : CVI|February 20, 2009
Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccineYichuan Wang, Shelley A Blozis, Michael Lederman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 26, 2002
CCR5 and CXCR4 expression after highly active antiretroviral therapy (HAART)Kimberly Y Smith, Sampath Kumar, Joseph J Pulvirenti, et al.
AIDS (London, England)|June 29, 2013
GB virus C infection and B-cell, natural killer cell, and monocyte activation markers in HIV-infected individualsJack T Stapleton, Jeffrey A Martinson, Donna Klinzman, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2023
Machine learning based gut microbiota pattern and response to fiber as a diagnostic tool for chronic inflammatory diseasesMiad Boodaghidizaji, Thaisa Jungles, Tingting Chen, et al.
AIDS (London, England)|February 20, 2015
Plasma levels of cytokines and chemokines and the risk of mortality in HIV-infected individuals: a case-control analysis nested in a large clinical trialMartyn A French, Alessandro Cozzi-Lepri, Roberto C Arduino, et al.
AIDS (London, England)|April 21, 2011
Resumption of HIV replication is associated with monocyte/macrophage derived cytokine and chemokine changes: results from a large international clinical trialAlessandro Cozzi-Lepri, Martyn A French, John Baxter, et al.
Pageof 23

Showing results (31-40 of 222) with videos related to

Sort By:
Pageof 23
Immunology|January 10, 2003
CD1d-restricted natural killer T cells are potent targets for human immunodeficiency virus infectionRichardson Fleuridor, Brian Wilson, Runhua Hou, et al.
The Journal of Infectious Diseases|July 11, 2003
Correlates of immune activation marker changes in human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women who use illicit drugsAlan Landay, Lorie Benning, James Bremer, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|February 5, 2011
A randomized trial of interleukin-2 during withdrawal of antiretroviral treatmentRonald J Bosch, Richard B Pollard, Alan Landay, et al.
AIDS Research and Therapy|August 7, 2010
Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328)Ronald J Bosch, Richard B Pollard, Alan Landay, et al.
Clinical and Vaccine Immunology : CVI|February 20, 2009
Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccineYichuan Wang, Shelley A Blozis, Michael Lederman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 26, 2002
CCR5 and CXCR4 expression after highly active antiretroviral therapy (HAART)Kimberly Y Smith, Sampath Kumar, Joseph J Pulvirenti, et al.
AIDS (London, England)|June 29, 2013
GB virus C infection and B-cell, natural killer cell, and monocyte activation markers in HIV-infected individualsJack T Stapleton, Jeffrey A Martinson, Donna Klinzman, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2023
Machine learning based gut microbiota pattern and response to fiber as a diagnostic tool for chronic inflammatory diseasesMiad Boodaghidizaji, Thaisa Jungles, Tingting Chen, et al.
AIDS (London, England)|February 20, 2015
Plasma levels of cytokines and chemokines and the risk of mortality in HIV-infected individuals: a case-control analysis nested in a large clinical trialMartyn A French, Alessandro Cozzi-Lepri, Roberto C Arduino, et al.
AIDS (London, England)|April 21, 2011
Resumption of HIV replication is associated with monocyte/macrophage derived cytokine and chemokine changes: results from a large international clinical trialAlessandro Cozzi-Lepri, Martyn A French, John Baxter, et al.
Pageof 23